Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase versus standardized medical therapy for mild disabling ischemic stroke with anterior circulation large vessel occlusion beyond 4.5 hours
ChiCTR2600131721Phase 3Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Proportion of patients with modified Rankin Scale score 0-1 at 90 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600131721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131721.